NASDAQ:ORMPOramed Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Oramed Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.17 -0.01 (-0.31 %) (As of 04/10/2020 06:03 AM ET) Add Compare Share Today's Range$3.11Now: $3.17▼$3.2350-Day Range$2.60MA: $3.54▼$5.0152-Week Range$2.32Now: $3.17▼$6.05Volume38,000 shsAverage Volume127,715 shsMarket Capitalization$56.56 millionP/E RatioN/ADividend YieldN/ABeta1.89 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule for the treatment of diabetes; and ORMD-0901, an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes. It is also developing a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingOramed Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.83, Oramed Pharmaceuticals has a potential upside of 241.7% from its current price of $3.17.Amount of Analyst CoverageOramed Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 3.1 Community Rank Outperform VotesOramed Pharmaceuticals has received 290 “outperform” votes. (Add your “outperform” vote.)Underperform VotesOramed Pharmaceuticals has received 183 “underperform” votes. (Add your “underperform” vote.)Community SentimentOramed Pharmaceuticals has received 61.31% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Oramed Pharmaceuticals and other stocks. Vote “Outperform” if you believe ORMP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ORMP will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldOramed Pharmaceuticals does not currently pay a dividend.Dividend GrowthOramed Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Oramed Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 20.50% of the stock of Oramed Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 3.34% of the stock of Oramed Pharmaceuticals is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Oramed Pharmaceuticals are expected to decrease by -8.16% in the coming year, from ($0.98) to ($0.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oramed Pharmaceuticals is -6.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oramed Pharmaceuticals is -6.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOramed Pharmaceuticals has a P/B Ratio of 3.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.32 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ORMP Previous Symbol CUSIPN/A CIK1176309 Webhttp://www.oramed.com/ Phone844-967-2633Debt Debt-to-Equity RatioN/A Current Ratio5.72 Quick Ratio6.62Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.70 million Price / Sales20.95 Cash Flow$0.85 per share Price / Cash Flow3.74 Book Value$0.90 per share Price / Book3.52Profitability EPS (Most Recent Fiscal Year)$0.82 Net Income$-14,350,000.00 Net Margins-295.94% Return on Equity-43.25% Return on Assets-24.11%Miscellaneous EmployeesN/A Outstanding Shares17,841,000Market Cap$56.56 million Next Earnings DateN/A OptionableOptionable Receive ORMP News and Ratings via Email Sign-up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:ORMP Rates by TradingView Oramed Pharmaceuticals (NASDAQ:ORMP) Frequently Asked Questions How has Oramed Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Oramed Pharmaceuticals' stock was trading at $3.31 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ORMP stock has decreased by 4.2% and is now trading at $3.17. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Oramed Pharmaceuticals? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oramed Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Oramed Pharmaceuticals. How were Oramed Pharmaceuticals' earnings last quarter? Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) posted its quarterly earnings results on Thursday, January, 9th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.26) by $0.11. The biotechnology company earned $0.67 million during the quarter. Oramed Pharmaceuticals had a negative net margin of 295.94% and a negative return on equity of 43.25%. View Oramed Pharmaceuticals' earnings history. What price target have analysts set for ORMP? 3 Wall Street analysts have issued 1-year price objectives for Oramed Pharmaceuticals' stock. Their forecasts range from $5.50 to $20.00. On average, they expect Oramed Pharmaceuticals' stock price to reach $10.83 in the next twelve months. This suggests a possible upside of 241.7% from the stock's current price. View analysts' price targets for Oramed Pharmaceuticals. Has Oramed Pharmaceuticals been receiving favorable news coverage? News stories about ORMP stock have trended very negative on Friday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Oramed Pharmaceuticals earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutOramed Pharmaceuticals. Who are some of Oramed Pharmaceuticals' key competitors? Some companies that are related to Oramed Pharmaceuticals include Minerva Neurosciences (NERV), MannKind (MNKD), Aduro BioTech (ADRO), Geron (GERN), Arcturus Therapeutics (ARCT), XOMA (XOMA), Abeona Therapeutics (ABEO), Recro Pharma (REPH), Lexicon Pharmaceuticals (LXRX), MediciNova (MNOV), Paratek Pharmaceuticals (PRTK), Protagonist Therapeutics (PTGX), NuCana (NCNA), OptiNose (OPTN) and Hookipa Pharma (HOOK). What other stocks do shareholders of Oramed Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oramed Pharmaceuticals investors own include TransEnterix (TRXC), Compugen (CGEN), Sarepta Therapeutics (SRPT), Inovio Pharmaceuticals (INO), Zynerba Pharmaceuticals (ZYNE), Gilead Sciences (GILD), Pluristem Therapeutics (PSTI), Novavax (NVAX), NovaBay Pharmaceuticals (NBY) and Corbus Pharmaceuticals (CRBP). Who are Oramed Pharmaceuticals' key executives? Oramed Pharmaceuticals' management team includes the following people: Mr. Nadav Kidron, CEO, Pres & Exec. Director (Age 45)Dr. Miriam Kidron, Chief Scientific Officer, Chief Medical & Technology Officer and Director (Age 79)Ms. Hilla Eisenberg CPA, CFO, Treasurer & Sec. (Age 35)Dr. Roy Eldor M.D., Ph.D., Chief Medical Advisor & Member of the Scientific Advisory Board What is Oramed Pharmaceuticals' stock symbol? Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP." How do I buy shares of Oramed Pharmaceuticals? Shares of ORMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Oramed Pharmaceuticals' stock price today? One share of ORMP stock can currently be purchased for approximately $3.17. How big of a company is Oramed Pharmaceuticals? Oramed Pharmaceuticals has a market capitalization of $56.56 million and generates $2.70 million in revenue each year. The biotechnology company earns $-14,350,000.00 in net income (profit) each year or $0.82 on an earnings per share basis. View additional information about Oramed Pharmaceuticals. What is Oramed Pharmaceuticals' official website? The official website for Oramed Pharmaceuticals is http://www.oramed.com/. How can I contact Oramed Pharmaceuticals? Oramed Pharmaceuticals' mailing address is 1185 AVENUE SUITE 228, NEW YORK NY, 10036. The biotechnology company can be reached via phone at 844-967-2633 or via email at [email protected] This page was last updated on 4/10/2020 by MarketBeat.com StaffFeatured Article: What is a short straddle?
